Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zinser, G. M.
Right arrow Articles by Welsh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinser, G. M.
Right arrow Articles by Welsh, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 23, No. 12, 2103-2109, December 2002
© 2002 Oxford University Press


CARCINOGENESIS

Vitamin D3 receptor ablation sensitizes skin to chemically induced tumorigenesis

Glendon M. Zinser1, John P. Sundberg2 and JoEllen Welsh1,3

1 Department of Biology, University of Notre Dame, Notre Dame, IN 46556, USA and
2 The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609-1500, USA

1,25-Dihydroxyvitamin D3 (1,25D3) is the biologically active form of vitamin D3 that interacts with the nuclear vitamin D3 receptor (VDR) to modulate gene expression in a tissue-specific fashion. 1,25D3 is a potent regulator of cell proliferation, differentiation and apoptosis in a variety of cell types, including keratinocytes. In these studies, we assessed the sensitivity of mice homozygous for a null allele of the VDR (VDR-/- mice) and their wild-type counterparts (VDR+/+ mice) to oral administration of the carcinogen 7,12-dimethylbenzanthracene (DMBA). Although the protocol was optimized for the induction of mammary tumors, 85% of VDR-/- mice developed persistent skin tumors within 60 days of carcinogen exposure. In VDR-/- mice exposed to DMBA, papillomas arose on all areas of the body, with an average tumor burden of 5.3 papillomas/mouse. No papillomas or any other skin lesions were observed in age- and sex-matched VDR+/+ mice dosed with DMBA and followed for 6 months. The majority (80%) of skin tumors that developed in VDR-/- mice were classified histologically as sebaceous, squamous or follicular papillomas. Other types of lesions, including basal cell carcinoma, hemangioma and melanotic foci, were occasionally observed in VDR-/- mice (but not in VDR+/+ mice) exposed to DMBA. Quantification of epidermal thickness and BrdU incorporation indicated that skin from VDR-/- mice exhibited hyperproliferation beginning at 7 weeks of age, which was exacerbated by DMBA treatment. Untreated aging VDR-/- mice did not exhibit tumor formation, but did develop a progressive skin phenotype characterized by thickened wrinkled skin, dermoid cysts and long curly nails. Together with previous reports that 1,25D3 inhibits papilloma formation induced by topical DMBA-TPA regimens, our observation of enhanced sensitivity of VDR-/- mice to chemically induced skin carcinogenesis offers compelling evidence that disruption of VDR signaling predisposes to neoplasia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BloodHome page
F. Gobel, S. Taschner, J. Jurkin, S. Konradi, C. Vaculik, S. Richter, D. Kneidinger, C. Muhlbacher, C. Bieglmayer, A. Elbe-Burger, et al.
Reciprocal role of GATA-1 and vitamin D receptor in human myeloid dendritic cell differentiation
Blood, October 29, 2009; 114(18): 3813 - 3821.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
H. S. CROSS, T. NITTKE, and M. PETERLIK
Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention
Anticancer Res, September 1, 2009; 29(9): 3705 - 3712.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Chung, G. Han, M. Seshadri, B. M. Gillard, W.-d. Yu, B. A. Foster, D. L. Trump, and C. S. Johnson
Role of Vitamin D Receptor in the Antiproliferative Effects of Calcitriol in Tumor-Derived Endothelial Cells and Tumor Angiogenesis In vivo
Cancer Res., February 1, 2009; 69(3): 967 - 975.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Endocr. Rev., October 1, 2008; 29(6): 726 - 776.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. I. Ellison, R. L. Eckert, and P. N. MacDonald
Evidence for 1,25-Dihydroxyvitamin D3-independent Transactivation by the Vitamin D Receptor: UNCOUPLING THE RECEPTOR AND LIGAND IN KERATINOCYTES
J. Biol. Chem., April 13, 2007; 282(15): 10953 - 10962.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. Nagpal, S. Na, and R. Rathnachalam
Noncalcemic Actions of Vitamin D Receptor Ligands
Endocr. Rev., August 1, 2005; 26(5): 662 - 687.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Nakagawa, A. Kawaura, S. Kato, E. Takeda, and T. Okano
1{alpha},25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer
Carcinogenesis, February 1, 2005; 26(2): 429 - 440.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J. Welsh
Vitamin D and breast cancer: insights from animal models
Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1721S - 1724S.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. M. Zinser and J. Welsh
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice
Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
D. D. Bikle
Vitamin D and Skin Cancer
J. Nutr., December 1, 2004; 134(12): 3472S - 3478S.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.